The company intends to use the funds to complete a Phase 2/3 registrational clinical trial evaluating ABC008, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of inclusion body myositis (IBM), and a Phase 1/2 clinical trial of ABC008 in T cell large granular lymphocytic leukemia (T-LGLL), as well as to initiate a Phase 1/2 clinical trial in T and NK cell lymphomas.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

90 Bridge St. 100
Newton, MA 02458
USA

Phone

(617) 714-9759

Website

www.abcuro.com

Email Address

[email protected]

Overview

We are developing first-in-class immunotherapies for autoimmune diseases and cancer through precise elimination or modulation of cytotoxic T and NK cells via KLRG1. We believe this strategy will result in therapeutics with reduced toxicity compared to existing therapeutic approaches for T cell modulation.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Steven Greenberg

Chief Executive Officer

David de Graaf

Chief Financial Officer

David Neafus

Chief Medical Officer

Richard Polisson

Chief Operating Officer

Evan Thompson

Chief Scientific Officer

Stefano Gulla

Browse more venture capital transactions:

Prev: 8/18/2023: FINEOS venture capital transaction
Next: 8/18/2023: Comptek Solutions venture capital transaction

Share this article

About Our VC Transactions Data

Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary